Economic Observer reporter Zhang Ying and Liu Xiaonuo

On May 28th, a screenshot circulating in the pharmaceutical industry showed that one of the reasons for the recent heated discussion in the industry about the suspected innovative drug BD regulation was that Beijing enterprise Bangyao packaged and sold its slow virus editing platform and IP, which attracted regulatory attention. The core issue was that the enterprise used a state-owned gene bank, involving national gene security.

The Economic Observer noted that currently, the only Chinese company engaged in gene editing business with "Bangyao" in its name is Shanghai Bangyao Biotechnology Co., Ltd., which has a branch in Beijing.

On May 29th, the CEO of Bangyao Biotechnology responded to the Economic Observer: Bangyao Biotechnology does not have the "slow virus editing platform" mentioned in the screenshot for external packaging and sale; The company has not received any offer or offer for the so-called 'IP package sale'; The company has never received any interviews, investigations, or special attention from relevant regulatory authorities regarding the matters described in the screenshot.

It is worth noting that there is currently no publicly available information regarding the other content mentioned in the screenshot circulating online, and the Economic Observer has not found any recent public statements from Shanghai Medical Insurance Bureau staff regarding this matter.

A screenshot circulating within the pharmaceutical industry